Xtant Medical Partners With B2i Digital to Highlight Orthobiologics Innovation

Xtant Medical Holdings has entered a partnership with B2i Digital to provide investor-focused content, aiming to highlight its orthobiologics platform and long-term value proposition. This collaboration is set to offer insights into Xtant's vertically integrated model, which encompasses a wide range of regenerative medicine products and medical devices for orthopedic and neurosurgical applications.

David Shapiro, CEO of B2i Digital, emphasized the significance of Xtant's position in the medical technology sector, noting its comprehensive product line and robust R&D pipeline. Sean Browne, CEO of Xtant Medical, expressed optimism about the partnership's role in communicating the company's growth narrative and value to the investment community.

With reported fiscal year 2024 revenue of $117.5 million, marking a 29% increase from the previous year, Xtant Medical demonstrates strong business fundamentals. The company's extensive distribution network and product pipeline are key assets in the competitive orthobiologics market, estimated at $2.5 billion in the U.S. within a $10.1 billion global spine market.